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Abstract
Radiotherapy aims to destroy tumors by inducing DNA damage in their cells at the local
irradiation site. Its immune-mediated systemic effects, called abscopal effect, has shown to
enhance anti-tumor immunity when combined with immune therapies and thus, have gained
attention by researchers and clinicians to investigate. Below is a summary of the fundamentals of
cancer and the immune system’s response to it, as well as the changes in the phenotype and
microenvironment of tumor cells after exposure to radiation. Impacts of the abscopal effect and
the induction of effective antitumor immunity with various immune therapy strategies will be
outlined. The emphasis is set on combination strategies of local radiation therapy with immune
therapies such as growth factor inhibitors and immune-checkpoint inhibitors. Limitations
Finding the most effective immune therapy in conjunction with radiation and optimizing these
therapies to be more patient-centered, offers the potential to improve anti-cancer treatments in
the future.
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Immunization by Radiotherapy: Enhancing an Immune-mediated Abscopal Effect
Introduction
Radiotherapy plays a vital role in cancer
treatment. It not only has the ability to affect
the DNA of the local tumor, but it also
produces systemic and immune-mediated
antitumor immunity (Deloch et al., 2016).
These effects are enhanced when
radiotherapy is used in combination with
other therapies that activate the immune
system (Frey & Gaipl, 2015). This review
focuses on the induction of local and
systemic antitumor immune responses by
radiotherapy
and
combined
immunotherapies.
The number of cancer incidences is expected
to increase by over 70% over the next 20
years, according to the World Health
Organization (Steward & Kleihues, 2017),
which presents the need for researchers and
clinicians alike to find effective antitumor
treatments.
Cancer and the immune system
The basics of cancer
Cancer is a condition that is manifested by the
presence of one or another type of neoplastic
growth—a malignant tumor (Weinberg,
2014). The cells that make up these
neoplastic tissues have manipulated the
versatile and autonomous nature of normal
cells. These individual cells also gain
normally denied access to their genomic
information and adopt roles that are deemed
inappropriate for maintenance and function
of normal tissues (Chen & Mellman, 2013).
Additionally, with increased genomic
instability, the cell becomes progressively
susceptible to mutations which can further
influence an abnormal phenotype. Simply
put, normal cells function to collaborate with

each other in order to maintain organismic
survival. On the other hand, cancer cells care
little about function and have a more focused
agenda—growing as much as possible and
creating more copies of themselves
(Weinberg, 2014).
Cancer is a genetic disease that is an
accumulation of exposure to environmental
carcinogens and random DNA mutations
(Chen & Mellman, 2013). Mutations lead to
a cascade of events that start with a change in
DNA. Mutated DNA can cause changes in
the mRNA product which influence changes
in the amino acid sequences and further
changes in protein structure and function.
There are two types of mutations, somatic
and germ-line. Germ-line mutations are
inherited mutations, passed down to
offspring that ultimately increase their
susceptibility to acquire that type of cancer.
Somatic mutations are not inherited but
changes in the DNA sequence caused by
random mutations accumulated over time
(Weingberg, 2014). They include two
categories: loss of function and gain of
function mutations. Loss of function
mutations occur in tumor suppressor genes,
which are specific genes that encode a protein
that functions to inhibit survival and
proliferation signals in normal cells. Tumor
suppressor genes are recessive in nature.
These recessive genes require two mutates
copes (one maternal and one paternal) to
yield a loss of function in the protein, leading
to the survival and proliferation of cancer
cells. Gain of function mutations occur in
proto-oncogenes, which are genes that
encode a protein that promotes cellular
growth and survival. Proto-oncogenes are
dominant in nature and can be activated to an
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oncogene by a gain of function mutation in
only one copy of the gene. This leads to
constitutive activity of the protein and
continuous downstream signaling of various
mechanisms of cellular growth (Chen &
Mellman, 2013). However, even in protooncogenes and tumor-suppressor gene the
mutations are random events, thus, it is
possible to speculate that cancer is just a
combination of mutated susceptible genes
and unfortunate luck.
Tumors with the ability to metastasize can
move around, unrestricted within the
confines of the body through blood and
lymphatic vessels and may establish novel
colonies of cancer cells in distant tissues. The
newly established colonies, or metastases,
can be directly traced back to the site where
the cancer began, termed the primary tumor
(Formenti & Demaria, 2013). For unknown
reasons, tumors in certain tissues have a high
probability of metastasizing and tumors from
different tissues almost never do. The
colonization of sites distant to the primary
tumor is a complex seven-step process
sometimes referred to as the invasionmetastasis cascade that relies heavily on
signals from the surrounding environment
(Gajewski et al., 2006).
The tumor microenvironment (TME) houses
many different types of cells alongside
cancer cells such as fibroblastic cells,
lymphocytes,
bone
marrow-derived
inflammatory cells, and an extracellular
matrix (ECM) composed of proteoglycans
and collagen (Gajewski et al., 2013). The
discovery that the stromal microenvironment
of tumors has closely related characteristics
to normal wounded tissues that do not heal
has been recognized for over a century
(Weinberg, 2014). However, the more recent
discovery concerning its role in stimulating
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an immune response to attach the cancer
cells, known as adaptive immunity, was
discovered in 1960 (Schumacher &
Schreiber, 2015). The former discovery still
has relevance in that chronic inflammation
plays a necessary role in promoting tumor
formation. It has been thought that
macrophages, a type of inflammatory cell,
have traditionally been the first line defense
against invaders where they consume them
and aid in the cascade of immune cell
activations through antigen presentation
(Gajewski et al., 2013). Other than in the
invasion-metastasis cascade, there is
evidence that macrophages sent to eradicate
the invader also function as sources of tumor
promotion. Their role in tumor promotion
stems from their production of mitogenic
growth factors, liberation of angiogenic
factors, and remodeling of the ECM
(Gajewski et al., 2006). More and more cells
of the immune system that are primarily
released to protect the body from infection as
well as cancer, are found to be major
components in the development of the latter.
Paradoxically, further experiments in mice
subjected to germ-line reengineering, where
one or another type of cell form the immune
system was deleted, resulted in the organism
being
less
capable
of
supporting
tumorigenesis, and thus was more
immunogenic (Weinberg, 2014).
Immune response to cancer
To be effective in killing cancer cells, the
immune response mounted against cancer
cells must initiate a series of events an
eventually produce the expansion of
specifically adapted immune cells to their
target (Frey et al., 2014). In the first step of
this cycle, neoantigens produced by
oncogenesis are seized after cancer cell death
by nonspecific dendritic cells (DCs) and
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processed. Unless peripheral tolerance to
these neoantigens is induced, additional
signals must be present at this step for an
antitumor T-cell response to be mounted.
These signals can include various proinflammatory cytokines and factors released
from dying cancer cells (Schumacher &
Schreiber, 2015). After processing, The DCs
present the antigen on their MHCI and
MHCII molecules to the T-cell receptors
(TCRs) of helper and cytotoxic T-cells. This
binding, along with other expressed
complimentary costimulatory molecules,
enables the priming of effector T-cells and
subsequent activation. This results in effector
T-cell responses against cancer-specific
antigens viewed as non-self or against those
from incomplete central tolerance (Reits et
al., 2006). The activated T-cells that
complete central tolerance travel from the
lymph node through lymph and blood vessels
to infiltrate the tumor bed, where it will
specifically recognize and bind it’s TCR
MHCI of the target cancer cell and kill it. The
killing of cancer cells releases more tumor
antigens that then stimulates an increased
immune response that ultimately promotes a
faster and more specific response in
subsequent response cycles (Weinberg,
2014). However, this cycle does not always
yield effective T-cell killing machines. For
example, tumor antigens may not be
detected, and/or they might be recognized as
self rather than non-self, resulting in T
regulatory cell (Treg) responses rather than
effector T-cell responses (Chen & Mellman,
2013).
The derivation of the antigens that permit the
immune system to differentiate malignant
cells from nonmalignant cells has been
unknown for a long time (Tureci et al., 2016).
However, we do know that the body’s T-cell
repertoire can recognize peptide epitopes on
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the surface of malignant cells via the highly
specific major histocompatibility complexes
(MHCs). The theoretical explanations for the
origin on these cancer rejection epitopes
involve the derivation from two classes of
antigens (Schumacher & Schreiber, 2015).
The first class of possible antigens is made by
non-mutation proteins to which incomplete
T-cell tolerance occurs due to their limited
tissue expression pattern. The second class of
possible cancer rejection antigens are made
from peptides that are completely absent
from the normal human genome—
neoantigens. The large group of human
tumors without a viral etiology are
exclusively created by tumor-specific
alterations in DNA that produce new protein
sequences (Schumacher & Schreiber, 2015).
The repertoire of neoantigens expressed in
cancer at the point it is clinically apparent
may be influenced substantially by the
interaction of the developing tumor with the
immune system (Schumacher & Schreiber,
2015). Cancer progresses and develops in the
body in three phases. During the first phase,
the immune system senses tissue changes
during neoplastic transformation and releases
chemicals, such as cytokines, to alert other
immune cells to the area. Here, the innate and
adaptive immune responses recognize the
transformed tissue and attempt to eradicate it
before it become clinically detectable This is
the elimination phase (Whiteside, Demaria,
Rodriguez-Ruiz, Zarour, & Melero, 2016). If
elimination is incomplete, the cells that
survived the initial immune response have
generated escape mutants due to genomic
instability. However, tumor proliferation is
equal to tumor killing and, is thus, called the
equilibrium phase. To tip the scales in favor
of tumor survival and proliferation, the
tumor’s neoantigens and associated epitopes,
recognized by T-cells, are constantly
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generated. This leads to the escape phase,
where a loss of more immunogenic antigens
causes the immune system to no longer
mount an effective killing response (Derer et
al., 2015). Thus, the tumor acquires
resistance to immune rejection and now can
be clinically detectable Therefore, strategies
such as radiotherapy, which mediates the
immunogenic release of tumor antigens,
along with ways to upset the body’s natural
immunosuppressive dominance, provide the
environment to recover the efficacy of
immunotherapies (Whiteside et al., 2016)
Abscopal Effect
Local radiation
antitumor vaccine

promotes

systemic

The application of local radiotherapy, in
combination with targeted immunotherapies,
where the radiation acts as an antitumor
vaccine on tumors outside the radiation field,
is a phenomenon known as the abscopal
effect (Reynders, Illidge, Siva, Chang, & De
Ruysscher, 2015). First proposed by Mole in
1953, the term “abscopal effect” was derived
from the Latin “ab” (away from) and
“scopos” (target), referring to the systemic
effects of local radiation on distant
nonirradiated tumor sites in animals after
treatment. (Mozdarani, 2012). This rare but
well-documented event represents a
paradigm shift in cancer therapy—some
effects of radiation are seen as beneficial and
contribute to the regression of the local
primary tumor as well as its metastases
(Formenti & Demaria, 2013).
The generalized objective of radiotherapy is
to deposit maximum dose of ionizing
radiation in the tumor while sparing healthy
tissue (Demaria, Golden, & Formenti, 2015).
Radiation uses localized beams of intense
energy to cause catastrophic DNA damage
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which produces highly radical oxygen
species (ROS) that further damage DNA. The
DNA damage checkpoint then arrests the
tumor cell from advancing through the cell
cycle and employs repair pathways (Deng et
al., 2014). If the various DNA damage
response mechanisms are unable to
compensate the damage, tumor cell death
occurs. The apoptotic tumor remnants are
phagocytized by nonspecific, antigenpresenting cells (APCs) in the area and
presented on their MHC class I molecules to
await adaptive immune cells (Derer et al.,
2015).
Other non-apoptotic tumor cells at the
irradiated site still undergo DNA damage but
are either unable to sense the damage or are
unable send the signal due to prior mutations
that inhibit these steps. Therefore, when the
tumor cell machinery senses this damage,
instead of signaling apoptosis, it releases
signals like damage-associated molecular
patterns (DAMPs), pathogen-associated
molecular
patterns
(PAMPs),
and
chemokines to enlist the help of
inflammatory cells to the TME (McBride et
al., 2004). The proinflammatory modifiers
responsible for recruiting effector cytotoxic
and helper T-cells are the chemokines
CXCL9, CXCL10 and CXCL16 and the
cytokines interleukin 1β tumor necrosis
factor α (TNF-α) and interferon γ (IFN-γ)
type 1 and 2 (Lugade et al., 2008). TNF-α
and IFN-γ also promote the maturation and
cross-presentation of DC’s. As these help
signals are being sent, tumor cells undergo
changes in their phenotype that augment their
susceptibility to and recognition by recruited
immune effectors. Some of these phenotypic
changes include the increased expression of
death receptors, MHC class I molecules,
costimulatory molecules, adhesion molecule
and stressed induced ligands (Reits et al.,
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2006). primes the tumor cells which allows
them, and the already primed APCs to
communicate with the recruited B- and Tlymphocytes to activate their effector
functions.
Various mechanisms have been proposed to
explain the abscopal effects of radiotherapy.
While we know that radiation causes
inflammation that induces the activation of
antigen-presenting DCs (Gupta et al., 2012),
the integral events leading up to the final
effect, are poorly understood. Patient specific
tumor heterogeneity and unpredictability as
well as the individualized immune response
to the tumor, further complicate our
understanding of the necessities for induction
(Tureci et al., 2016). Although, recent studies
have shown that an adaptor protein known as
the stimulator of interferon genes (STING), a
main contributor in innate immunity, is one
requirement for the antitumor effect of
radiation and the introduction of type I IFNs
(Deng et al., 2014). Adaptor proteins are
responsible in intracellular signaling
pathways where they regulate gene
transcription. In regards to cancer, the
STING pathway operates by using its
cytoplasmic pattern recognition receptor to
sense radiation-induced, tumor-released
DNA (Rodriguez-Ruiz et al., 2016). The
importance of type I IFNs has been
elucidated by the prior research of Burnette et
al. (2011) testing mice either lacking or not,
the type I IFN receptor (IFNAR-/-). They
found that cytotoxic T-cell function depends
on their radiation-induced presence in the
TME. As mentioned before, IFNs are a class
of proinflammatory proteins that enhance
cross-presentation to activate the specific
adaptive immune response. The STING
pathway bridges that gap between innate and
adaptive immunity and in response to
radiation, is crucial for the spontaneous
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generation of antitumor T-cell responses
against immunogenic tumors (Woo et al.,
2015). However, the diverse range of stimuli
needed to generate type I IFN production, as
seen in the various nucleic acid-sensing
pathways, together with the unknown
identity of immune cells that carry out type I
IFN responses after radiation, exemplify the
difficulties of inducing the abscopal effect.
Recent data suggest that radiotherapy
increases these responses, thereby providing
a potential explanation to this rather elusive
event (Deng et al., 2014).
The uncommon occurrence of abscopal
effects observed in cancer patients reflects
only one barrier to effective tumor rejection.
For cytotoxic T-cells to reject a tumor, a set
of sequential steps must be followed. First,
T-cells must be able to home correctly to the
tumor site by extravasating from vessels to
access the tumor microenvironment.
Secondly, it is imperative for T-cells to retain
their effector functions once they arrive at the
tumor site. Lastly, stable immunological
synapses must be established between the
tumor cell and the effector T-cell (Gajewski
et al., 2006). In each of these steps, there are
multiple obstacles to overcome due to the
complex nature of signaling pathways and
their messengers.
Another critical barrier to priming of T-cell
responses to various tumor antigens, induced
by radiotherapy, is the protein known as
transforming growth factor beta (TGFβ)
(Kang, Demaria, & Formenti, 2016). This
cytokine is important in promoting the
differentiation of immunosuppressive T-cell
subsets, like regulatory T-cells (Tregs) which
mediate immune responses from becoming
harmful to the body. Therefore, when ROS
are produced as a consequence of
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radiotherapy, they convert latent TGFβ to its
active form (Vanpouille-Box et al., 2015).
While radiation promotes the release of proimmunogenic signals to the tumor site, it also
promotes immunosuppressive mechanisms.
Therefore, its ability to induce an immunemediated abscopal effect most likely depends
on altering the pre-existing tumor
microenvironment to shift the balance to
favor an immunostimulatory one (Gajewski
et al., 2013). Despite how the positive effects
of radiation generally outweigh the negative
effects, without targeted immunotherapy,
radiation alone is not insufficient to shift the
balance to accomplish tumor rejection and
control metastatic progression (Formenti &
Demaria, 2013). The therapeutic applications
of radiotherapy as well as chemotherapy,
whether stand-alone or in conjunction with
targeted immunotherapies, should stimulate
local and systemic tumor control by the
promotion of immunogenic cell death, which
can induce persistent antitumor responses by
the immune system. (Gaipl et al., 2014).
Effects
enhanced
strategies

by

combination

The application of ionizing radiation to
cancer therapeutics has long been established
due to the combination of its cytocidal
influence and selectivity in targeting tumors
(Demaria et al., 2015). However, in the past
two decades, the concept was proposed to
combine local radiation treatment with
immunotherapy to induce an abscopal effect
focused on inhibiting metastatic growth
(Shiraishi et al., 2008).
Combination strategies from these clinical
trials utilized targeted immunotherapies to
enhance the effects of radiation, such as
influencing either the priming or effector
phases of antitumor immune responses
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(Formenti & Demaria, 2013). In one study,
cross-priming of antitumor T cells was
enhanced by the amplification of DC number
and function. This was demonstrated in mice
by the administration of DC growth factors
such as Flt3-ligand near the irradiated tumor
and by the injection of exogenously prepared
syngeneic DCs into the irradiated tumor for
which inhibition of spontaneous metastases
was observed in a lung carcinoma and breast
cancer, respectively (Chakravarty et al.,
1999). In a phase I trial, patients with hepatocellular carcinoma were intratumorally
injected with autologous DCs 2 days after
single fraction radiotherapy and a partial
abscopal response was seen in two out of 14
patients (Chi et al., 2005). In another study,
DCs injected into sarcomas during
fractionated radiotherapy, showed infiltration
of T-cells in the tumor at the time of surgery
with tumor-specific immune responses from
nine out of the 17 patients. A year later, 12
out of the 17 patients were progression-free
of their cancer (Finkelstein et al., 2012).
According to Hildner et al., crosspresentation to cytotoxic T-cells are mainly
regulated by a specialized subset of DCs that
depend on Baft-3 transcription factor and
Flt3-ligand as a growth factor for their
development (2008). Experiments to test
Baft-3-dependent DCs on the induction of
antitumor cytotoxic T-cells in Baft-3deficient mice revealed a loss of the abscopal
effect and a diminished control of the local
tumor. This suggests, to some extent the
critical role of IFNα/β on the therapeutic
effects from radiotherapy. Similarly, BATF-/and IFNAR-/- mice lost the radiation-induced
abscopal effects when treated with the
combination of anti-PD1 and anti-CD137
monoclonal antibodies, or mAbs (RodriguezRuiz et al., 2016). In addition, strategies
focused on the enhancing the local induction
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of IFNα/β have potential to elicit more
immunogenic tumor cell deaths induced by
combination treatments with radiotherapy.
The immunogenic cell death induced by
radiotherapy, however, only offers temporary
systemic control and may be due to the weak
immunization effects or because of factors
and mechanisms such as TGFβ that work in
tandem to suppress the immune system
(Vanpouille-Box et al., 2015). For example,
strategies tested in preclinical and clinical
trials to block TGFβ combined with
radiotherapy, have the potential to counteract
its immunosuppressive effects and to also
thwart DNA damage repair, angiogenesis,
and metastasis (Bouquet et al., 2011).
Strategies to promote the effector phase of
antitumor immunity have coupled T-cell
activation with an antibody that targets the
inhibitory checkpoint receptor CTLA-4
(cytotoxic T lymphocyte-associated antigen
4) after radiation therapy (Kang et al., 2016).
Currently being developed in the clinic,
mAbs that target receptors on immune cells
where they either remove coinhibitory
signals or supply costimulatory signals to
improve
antitumor
immunity.
The
combination of ipilimumab (an anti-CTLA-4
mAb) with radiotherapy currently has limited
clinical experience as there are only results
from two clinical trials that are now available
for prostate cancer and metastatic melanoma
(Twyman-Saint Victor et al., 2015). In a
preclinical study using anti-CTLA-4 mAbs, it
was shown that simultaneous positive
costimulation with inhibition of negative
costimulatory signals increased the avidity by
10-fold. Wherein, avidity is the concentration
of antigen required to elicit a T-cell response
after target loading (Poleszczuk et al., 2016).
Results from prospective clinical trials
combining radiotherapy with anti-CTLA has
shown success in non-small cell lung
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carcinoma (NSCLC). According to Golden et
al. (2015), since NSCLC is a tumor type that
is unresponsive when give anti-CTLA-4
alone, this gives hope that multiple tumor
types might also benefit from the
radiotherapy combinations.
Conclusion
Radiotherapy induces an immune-mediated
abscopal effect which is further enhanced
with the combination of immunotherapy to
produce a systemic antitumoral vaccine.
Targeted immunotherapies using growth
factor inhibitors and antibodies such as TGFβ
and anti-CTLA-4, respectively, have
reported effective antitumor induction (Derer
et al., 2015). Overall, these studies show
combination strategies are more effective
than any one strategy alone and may be
applicable to multiple cancer types in the
future.
Limitations
As mentioned above, one of the challenges
that researchers face is finding treatments
that promote tumor immunogenicity and
simultaneously hinder immunosuppression.
It is also crucial to gain knowledge on the
specific mechanisms and mediators involved
in the induction of an immune-mediated
abscopal effect, such as understanding
STING pathway, as well as information on
the identify and function of the specialized
subset of DCs responsible for T-cell crosspresentation
(Kang
et
al.,
2016).
Additionally, a more patient-specific
treatment could prove more effective when
considering their specific tumor type, stage of
progression, and immune cell repertoire.
Further investigation is needed to find the
optimal timing, dose and fractionization of
radiotherapy with combination strategies and
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how they depend the type of immunotherapy
used (Rodriguez-Ruiz et al., 2016).
Future Research
In general, strategies using radiotherapy to
induce systemic antitumor immunity, are
being tested in various preclinical trials, in
combination
with
immunomodulatory
interventions
that
either
block
immunosuppressive mechanisms or enhance
immune response activation. However, there
is much to be known about the effects of
targeting key activators or suppressors of the
immune system after radiation. Thus,
prospective research should focus on
combining multiple immune mediators with
radiation to augment the primer and effector
phases of antitumor immunity. These include
likely targets such as Baft-3, Flt3-ligand,
IFNα/β, TGFβ, anti-PD1, and anti-CTLA-4
(Deloch et al., 2016).
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Appendix A
American Psychological Associated (APA) 6th edition was the format style used for this
literature review. According to the APA Publication Manual, the Title page should include a
running head, a title, the author’s name and the institutional affiliation. Following the Title page
is the Abstract, that is written as a single paragraph of 150-250 words. Next, the Table of
Contents page, where the first level is bold, centered, including upper and lowercase letters. The
second level headings are bold, left-aligned and capitalized first letter. The body contains the
introduction, discussion and conclusion that uses 12-point, Times New Roman font with the
paragraphs aligned to the left. A shortened version of the title of the paper was used as a header
for all subsequent pages after the title page. The References page appears at the end of the
document and includes references with a hanging indent. The in-text citations include the author
and the year of publication.
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Appendix B
In the process of editing my original version, I decided to restart my literature review paper with
a more focused topic and thus, documentation of feedback from my external reviewer was
unattainable. However, peer-reviewed suggestions were taken into consideration and most were
accepted.

